Department of Psychiatry and Psychotherapy, University of Bonn, Sigmund-Freud-Straße 25, DE-53105 Bonn, Germany.
Department of Psychiatry and Psychotherapy, University of Bonn, Sigmund-Freud-Straße 25, DE-53105 Bonn, Germany.
Eur Neuropsychopharmacol. 2014 Jan;24(1):86-94. doi: 10.1016/j.euroneuro.2013.07.003. Epub 2013 Aug 6.
A role of the HTR3A-E genes in obsessive-compulsive disorder (OCD) can be expected based on promising effects of 5-HT3 receptor antagonists as adjunctive treatment of OCD. We therefore genotyped six common coding or promoter variants within the HTR3A-E genes in a case-control-sample consisting of N=236 OCD patients and N=310 control subjects and in N=58 parent-child-trios. Given the heterogeneous OCD phenotype, we also investigated OCD symptom dimensions and cognitive endophenotypes in subsamples. OCD patients scoring high for the washing subtype were significantly more likely to carry the c.256G-allele of the HTR3E variant rs7627615 (p=0.0001) as compared to OCD patients low for this symptom dimension. Visual organization was impaired in OCD patients and unaffected relatives as compared to healthy control subjects and carriers of the HTR3E c.256G/c.256G-genotype performed significantly worse (p=0.007). The case-control analyses revealed a nominal significant association of the HTR3D variant rs1000592 (p.H52R) with OCD (p=0.029) which was also evident after combination of the case-control and the trio-results (p=0.024). In male subjects, the variant rs6766410 (p.N163K) located in the HTR3C was significantly associated with OCD (p=0.007). The association findings of the HTR3C and the HTR3E remained significant after correction for the number of variants investigated. These findings indicate a role of common variants of the HTR3A-E genes in OCD and OCD-related phenotypes and further support the use of 5-HT3 receptor antagonists as novel treatment options. The HTR3E gene is a novel candidate gene impacting on the individual expression of OC symptoms and OCD-related cognitive dysfunction.
基于 5-HT3 受体拮抗剂作为 OCD 辅助治疗的有希望的效果,可以预期 HTR3A-E 基因在强迫症 (OCD) 中的作用。因此,我们在包括 N=236 名 OCD 患者和 N=310 名对照在内的病例对照样本中对 HTR3A-E 基因中的六个常见编码或启动子变体进行了基因分型,并在 N=58 个父母-子女-三重样本中进行了基因分型。鉴于 OCD 的表型异质性,我们还在亚样本中研究了 OCD 症状维度和认知内表型。与这个症状维度得分低的 OCD 患者相比,在 HTR3E 变体 rs7627615 的 c.256G-等位基因中得分高的 OCD 患者更有可能携带该等位基因(p=0.0001)。与健康对照组和 HTR3E c.256G/c.256G 基因型携带者相比,OCD 患者和未受影响的亲属的视觉组织受损,表现明显更差(p=0.007)。病例对照分析显示 HTR3D 变体 rs1000592(p.H52R)与 OCD 存在名义上的显著关联(p=0.029),在结合病例对照和三重结果后也得到了证实(p=0.024)。在男性受试者中,位于 HTR3C 的变体 rs6766410(p.N163K)与 OCD 显著相关(p=0.007)。在对所研究的变体数量进行校正后,HTR3C 和 HTR3E 的关联发现仍然显著。这些发现表明 HTR3A-E 基因的常见变体在 OCD 和 OCD 相关表型中起作用,并进一步支持使用 5-HT3 受体拮抗剂作为新的治疗选择。HTR3E 基因是一个新的候选基因,它影响 OC 症状和 OCD 相关认知功能障碍的个体表达。